BCG polysaccharide + nucleic acid

BCG polysaccharide + nucleic acid (BCG-PSN) is an immunomodulatory biologic derived from a lipopolysaccharide fraction extracted from the Bacillus Calmette–Guérin (BCG) vaccine. It consists of bacterial polysaccharides and nucleic acids. Unlike live BCG vaccine, BCG-PSN does not contain viable mycobacteria but retains strong immunomodulatory properties. Its mechanism involves modulation of immune responses—downregulating Th17 lymphocyte subsets and associated cytokines (such as IL-17 and IL-23), reducing IgE levels, and influencing inflammatory pathways including interleukin 4, interleukin 13, and interleukin 31. Clinically, it has been used for the treatment of warts (verrucae), chronic urticaria, atopic dermatitis, lichen planus, asthma, vitiligo (often in combination with other therapies), and has shown higher efficacy with fewer side effects compared to live BCG vaccine in some indications[1][3][4][5][6][7]. Administration is typically by intralesional or intramuscular injection.

Brand names

卡介菌多糖核酸

Other names

Bacillus Calmette-Guerin polysaccharide nucleic acidBCG-PSN卡介苗多糖核酸Bacillus Calmette-Guérin polysaccharide and nucleic acid injection